Clinical Trials
6 trialsNCT07036133 2026-02-11
SPI-FOL-102
Acrotech Biopharma Inc.
Phase 1 Recruiting
NCT02594267 2021-07-27
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01789723 2020-01-23
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Acrotech Biopharma Inc.
Phase 1 Withdrawn
NCT01820091 2020-01-23
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Acrotech Biopharma Inc.
Phase 1 Withdrawn
NCT00554827 2020-01-03
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed